

Attorney Docket: 1830/50325
PATENT

#3
10/5/01
87

10/5/01 U.S. PTO

09/933717



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MASAHIRO IMOTO ET AL.

Serial No.: TO BE ASSIGNED Group Art Unit:

Filed: CONCURRENT HERewith Examiner:

Title: HETEROCYCLIC COMPOUNDS HAVING EFFECT OF ACTIVATING
NICOTINIC ACETYLCHOLINE $\alpha 4 \beta 2$ RECEPTOR

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.97 and 1.98

Commissioner for Patents
Washington, D.C. 20231

Sir:

In accordance with the duty of disclosure under 37 CFR §1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached Form PTO-1449 and/or listed herein and which the Examiner may deem relevant to patentability of the claims of the above-identified application.

In compliance with the concise explanation requirement under 37 CFR §1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a corresponding foreign Search Report citing such documents, together with an English-language version (if not already included) of that portion of the Search Report indicating the degree of relevance found by the foreign office.

The present Information Disclosure Statement is being filed (1) no later than three months from the application's filing date or (2) before the mailing date of the first Office


Serial No. TO BE ASSIGNED

Action on the merits (whichever is later), and therefore no certification under 37 C.F.R. §1.97(e) or fee under 37 C.F.R. §1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

If necessary, the paper should be considered as a petition for consideration of the Information Disclosure Statement under 37 C.F.R. §1.97(d)(2) and that the petition fee set forth in 37 C.F.R. §1.17(i) in accordance with 37 C.F.R. §1.97(d)(3) should be charged to Deposit Account No. 05-1323 (Docket #1830/50325).

Respectfully submitted,



Herbert I. Cantor
Registration No. 24,392

August 22, 2001

CROWELL & MORING, LLP
P.O. Box 14300
Washington, DC 20044-4300
Telephone No.: (202) 628-8800
Facsimile No.: (202) 628-8844

Form PTO-1449 U.S. Department of Commerce Patent & Trademark Office INFORMATION DISCLOSURE STATEMENT <i>(Use several sheets if necessary)</i>	Atty. Docket No. 1830/50325	Serial No. TO BE ASSIGNED
Applicant: Masahiro IMOTO, et al.		
Filing Date CONCURRENT HEREWITH		Group

 10970 U.S. PTO
 09/933717


U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
	AA	4956356	11/09/90	Diehr, et al.			
	AB	4298734	03/11/81	Temple, Jr.			
	AC	5736550	07/04/98	Kikuchi, et al.			
	AD	5547965	20/08/96	Krüger, et al.			
	AE						
	AF						
	AG						

FOREIGN PATENT DOCUMENTS

		Document	Date	Country	Class	Sub-class	Translation Yes No
	AK						
	AL						
	AM						
	AN						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	AQ	Latli, B.; D'Amour, K; Casida, J.E. Novel and potent 6-chloro-3-pyridinyl ligands for the alpha4beta2 neuronal nicotinic acetylcholine receptor. J. Med. Chem., Vol. 43, No. 12, pp. 2227-2234 (17 June, 1999) (Compounds 1-5, 8-10, 15) a
	AR	Zhao, S.; Freeman, J.P.; Bacon, C.L.; Fox, G.B.; O'Driscoll, E.; Foley, A.G.; Kelly, J.; Ferrell, U.; Regan, C.; Mizzak, S.A.; Szmuszkowicz, J. Syntheses of 1,2-diamino and 1,2-aminoalcohol derivatives in the piperidine and pyrrolidine series as anti-amnesic agents. Bioorg. Med. Chem., Vol. 7, No. 8, pp. 1647-1654 (1999 Aug.)
	AS	D'Amour, K.A.; Casida, J.E. Desnitroimidacloprid and Nicotine Binding Site in Rat Recombinant alpha4beta2 Neuronal Nicotinic Acetylcholine Receptor. Pestic. Biochem. Physiol, Vol. 64, No. 1, pp. 55-64 (1999 May)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

No References